The Current Ratio as of December 2024 (TTM) for uniQure N.V. (QURE) is 6.51

According to uniQure N.V.’s latest financial reports and current stock price. The company's current Current Ratio is 6.51. This represents a change of -18.87% compared to the average of 8.03 of the last 4 quarters.

uniQure N.V. (QURE) Historical Current Ratio (quarterly & annually)

How has QURE Current Ratio performed in the past?

The mean historical Current Ratio of uniQure N.V. over the last ten years is 9.37. The current 6.51 Current Ratio has changed 6.85% with respect to the historical average. Over the past ten years (40 quarters), QURE's Current Ratio was at its highest in in the December 2021 quarter at 17.09. The Current Ratio was at its lowest in in the March 2015 quarter at 3.15.

uniQure N.V. (QURE) Current Ratio by Quarter and Year

Discovering the peaks and valleys of uniQure N.V. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

uniQure N.V. (QURE) Average Current Ratio

How has QURE Current Ratio performed in the past?

The current Current Ratio of uniQure N.V. (QURE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

uniQure N.V. (QURE) Current Ratio vs. Peers

How is QURE’s Current Ratio compared to its peers?

uniQure N.V.’s Current Ratio is greater than Rocket Pharmaceuticals, Inc. (6.05), greater than Rhythm Pharmaceuticals, Inc. (3.49), less than Solid Biosciences Inc. (7.85), greater than MeiraGTx Holdings plc (2.34), less than Terns Pharmaceuticals, Inc. (32.99), greater than Amylyx Pharmaceuticals, Inc. (4.55), less than Acumen Pharmaceuticals, Inc. (10.43), less than Inozyme Pharma, Inc. (7.68), greater than X4 Pharmaceuticals, Inc. (4.89), less than Vaxcyte, Inc. (17.88), less than Larimar Therapeutics, Inc. (13.10), less than Syndax Pharmaceuticals, Inc. (6.99), less than Merus N.V. (8.32), greater than Sutro Biopharma, Inc. (3.09), greater than Kiniksa Pharmaceuticals, Ltd. (3.24), less than Day One Biopharmaceuticals, Inc. (14.62), less than Structure Therapeutics Inc. (27.63), less than Karuna Therapeutics, Inc. (19.31), greater than Phathom Pharmaceuticals, Inc. (5.73), greater than REGENXBIO Inc. (3.05), less than Replimune Group, Inc. (10.11), less than Avidity Biosciences, Inc. (17.76), less than Protagonist Therapeutics, Inc. (10.70),

Build a custom stock screener for uniQure N.V. (QURE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like uniQure N.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

uniQure N.V. (QURE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like uniQure N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.